Pacira BioSciences, Inc. (PCRX) Stock

Pacira BioSciences, Inc., headquartered in Tampa, Florida, specializes in advancing non-opioid pain management and regenerative health solutions for healthcare providers and their patients across the United States. Founded in 2006 as Pacira Pharmaceuticals, the company rebranded to Pacira BioSciences in April 2019, reflecting its commitment to innovative biotherapeutic approaches.

At the forefront of its offerings is EXPAREL, a bupivacaine liposome injectable suspension designed for sustained pain relief following surgeries. Additionally, Pacira markets ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide for the treatment of osteoarthritis-related knee pain. The company also innovates with the iovera system, a handheld cryoanalgesia device that delivers precise cold therapy to targeted nerves without opioids.

Pacira BioSciences leverages its proprietary multivesicular liposome technology, which enables the encapsulation of drugs while preserving their molecular integrity during delivery. This technology enhances the efficacy and duration of therapeutic effects, supporting the company's mission to provide effective pain management alternatives.

With a strategic focus on advancing patient care through science-driven innovation, Pacira collaborates with healthcare professionals to expand treatment options and improve outcomes in pain management and regenerative health. By combining cutting-edge research with clinical expertise, Pacira BioSciences continues to pioneer solutions that address critical unmet needs in healthcare.